Home
>
National Drug Code (NDC)
>
LEXIVA
LEXIVA - 49702-208-53 - (fosamprenavir calcium)
Drug Information of LEXIVA
| Product NDC: | 49702-208 |
| Proprietary Name: | LEXIVA |
| Non Proprietary Name: | fosamprenavir calcium |
| Active Ingredient(s): | 50 mg/mL & nbsp; fosamprenavir calcium |
| Administration Route(s): | ORAL |
| Dosage Form(s): | SUSPENSION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of LEXIVA
| Product NDC: | 49702-208 |
| Labeler Name: | ViiV Healthcare Company |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022116 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20101004 |
Package Information of LEXIVA
| Package NDC: | 49702-208-53 |
| Package Description: | 225 mL in 1 BOTTLE (49702-208-53) |
NDC Information of LEXIVA
| NDC Code | 49702-208-53 |
| Proprietary Name | LEXIVA |
| Package Description | 225 mL in 1 BOTTLE (49702-208-53) |
| Product NDC | 49702-208 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | fosamprenavir calcium |
| Dosage Form Name | SUSPENSION |
| Route Name | ORAL |
| Start Marketing Date | 20101004 |
| Marketing Category Name | NDA |
| Labeler Name | ViiV Healthcare Company |
| Substance Name | FOSAMPRENAVIR CALCIUM |
| Strength Number | 50 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],Cytochrome P450 3A4 Inhibitors [MoA] |
